Jounce Therapeutics (JNCE) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free JNCE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative November 27, 2023 | bizjournals.comSan Diego VC, OrbiMed make competing buyout offers for struggling TheseusSeptember 19, 2023 | tmcnet.comJounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply SourceSeptember 18, 2023 | finance.yahoo.comKargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce MediaSeptember 5, 2023 | tmcnet.comMediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce MediaMay 5, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $324KMay 4, 2023 | benzinga.comBoard Member at Jounce Therapeutics Exercises Options Worth $172KMay 4, 2023 | benzinga.comJounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock OptionsMay 4, 2023 | benzinga.comJounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock OptionsMay 4, 2023 | marketbeat.comTrading was temporarily halted for "JNCE" at 07:05 PM with a stated reason of "News pending."May 3, 2023 | finance.yahoo.comJounce Therapeutics Announces Closing of Tender OfferApril 30, 2023 | marketbeat.comJounce Therapeutics (NASDAQ:JNCE) Now Covered by StockNews.comStockNews.com initiated coverage on Jounce Therapeutics in a report on Sunday. They set a "hold" rating on the stock.April 29, 2023 | seekingalpha.comJNCE Jounce Therapeutics, Inc.April 17, 2023 | finance.yahoo.comThe past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitableMarch 29, 2023 | benzinga.comWhat is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?March 27, 2023 | msn.comBuyout Offer Sends Jounce Jumping 20%March 27, 2023 | marketwatch.comJounce Therapeutics Shares Rally on Buyout Deal >JNCEMarch 27, 2023 | marketwatch.comJounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCEMarch 27, 2023 | finance.yahoo.comJounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobsMarch 27, 2023 | marketbeat.comTrading was temporarily halted for "JNCE" at 08:03 AM with a stated reason of "News pending."March 23, 2023 | benzinga.comMoore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law FirmMarch 17, 2023 | 247wallst.comTang Capital Partners Now Owns 10.2% of Jounce TherapeuticsMarch 16, 2023 | finance.yahoo.comJounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerMarch 16, 2023 | finance.yahoo.comJounce (JNCE) Up 41% on Buyout Offer From Concentra BiosciencesMarch 15, 2023 | benzinga.com10% Owner of Jounce Therapeutics Makes $85K BuyMarch 15, 2023 | finance.yahoo.comWhy Jounce Therapeutics Stock Is Moving Higher Today?March 15, 2023 | markets.businessinsider.comConcentra Biosciences Proposes To Acquire Jounce Therapeutics - Quick FactsMarch 15, 2023 | msn.comTang Capital Partners Now Owns 10.20% of Jounce Therapeutics (JNCE)March 15, 2023 | marketwatch.comJounce Therapeutics Jumps Premarket on Buyout Bid >JNCEMarch 15, 2023 | investorplace.comWhy Is Jounce Therapeutics (JNCE) Stock Up 37% Today?March 15, 2023 | finance.yahoo.comJounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesMarch 13, 2023 | finance.yahoo.comJounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating accountMarch 11, 2023 | finance.yahoo.comJounce Therapeutics Full Year 2022 Earnings: Beats ExpectationsMarch 1, 2023 | benzinga.comMoore Kuehn Encourages ROCC, JNCE, BRMK, and FOCS Investors to Contact Law FirmMarch 1, 2023 | benzinga.comJOUNCE THERAPEUTICS INVESTOR ALERT by the Former...February 23, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Jounce Therapeutics, Inc. MergerFebruary 23, 2023 | finance.yahoo.comCambridge biotech Jounce to cut staff, merge with U.K. drug developerFebruary 23, 2023 | finanznachrichten.deJounce Therapeutics, Inc.: Redx and Jounce Announce Recommended Business CombinationFebruary 23, 2023 | marketwatch.comJounce Shares Bounce Higher on Tie-Up With Redx >JNCEFebruary 23, 2023 | markets.businessinsider.comRaymond James downgrades Jounce Therapeutics (JNCE) to a HoldFebruary 23, 2023 | msn.comJounce stock soars ~35% on all-stock merger with Redx PharmaFebruary 23, 2023 | finance.yahoo.comRedx and Jounce Announce Recommended Business CombinationFebruary 22, 2023 | marketwatch.comJounce Therapeutics Shares Up 12% After Hours On Layoff PlansFebruary 22, 2023 | finance.yahoo.comJounce Therapeutics Announces RestructuringJanuary 27, 2023 | marketbeat.comShort Interest in Jounce Therapeutics, Inc. (NASDAQ:JNCE) Declines By 46.3%Jounce Therapeutics, Inc. (NASDAQ:JNCE - Get Rating) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 1,580,000 shares, a decrease of 46.3% from the December 31st total of 2,940,000 shares. Based on an average trading volume of 1,550,000 shares, the days-to-cover ratio is presently 1.0 days. Approximately 4.0% of the shares of the stock are sold short.January 25, 2023 | nasdaq.comCowen Financial Products LLC Ups Stake in Jounce Therapeutics Inc (JNCE)January 20, 2023 | marketbeat.comJounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Sold by Trv Gp II LLCTrv Gp II LLC decreased its stake in Jounce Therapeutics, Inc. (NASDAQ:JNCE - Get Rating) by 57.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 572,829 shares of the company's stock after selling 775,000 shares duringJanuary 13, 2023 | marketbeat.comAssenagon Asset Management S.A. Sells 571,100 Shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE)Assenagon Asset Management S.A. lowered its stake in shares of Jounce Therapeutics, Inc. (NASDAQ:JNCE - Get Rating) by 41.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 800,291 shares of the company's stock after sellJanuary 12, 2023 | reuters.comJNCE.O - | Stock Price & Latest News | ReutersJanuary 4, 2023 | finance.yahoo.comGilead's (GILD) Application for Trodelvy Gets EMA ValidationDecember 28, 2022 | finance.yahoo.comGilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program Get Jounce Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Dems have chosen Biden replacement? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election. See who it is HERE. JNCE Media Mentions By Week JNCE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JNCE News Sentiment▼0.000.76▲Average Medical News Sentiment JNCE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JNCE Articles This Week▼00▲JNCE Articles Average Week Get Jounce Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CASI News CCCC News JSPR News AURA News TRML News AVXL News STRO News MGTX News TNYA News SOPH News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JNCE) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
